InDex Pharmaceuticals AB

InDex has entered into a conditional agreement regarding a reverse merger with Flerie. For more information please use the link below:

InDex Pharmaceuticals has entered into a conditional agreement regarding a reverse merger with Flerie - InDex Pharmaceuticals 20 May 2024 – InDex Pharmaceuticals Holding AB (publ) (

Today, InDex Pharmaceuticals Holding AB published the Annual Report for 2023. You can find it on InDex's website.

InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2023 - InDex Pharmaceuticals April 8, 2024 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2023. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports/.

Today, InDex Pharmaceuticals published the year-end report for 2023

InDex Pharmaceuticals Holding AB (publ) year-end report 2023 - InDex Pharmaceuticals Full focus on closing phase III program

InDex Pharmaceuticals announced yesterday that an independent Data Monitoring Committee (DMC) has completed the planned dose selection analysis, including safety review and assessment for futility in Induction Study 1 of the phase III program CONCLUDE.

The DMC advises that cobitolimod is unlikely to meet the primary endpoint upon completion of Induction Study 1. The advice to stop the study was not based on safety concerns.

“This surprising and disappointing news confirms the complexity of the disease and the need for further research within this field, especially as moderate to severe ulcerative colitis is an indication with high unmet medical need for new treatment options. We are incredibly grateful to all the patients, investigators and study personnel for their engagement to date,” says Jenny Sundqvist, CEO of InDex Pharmaceuticals. “We will conduct a comprehensive review of all the study data before announcing next steps.”

Click the link below for more information and login details to an investor call today at 3 pm CET.

InDex Pharmaceuticals discontinues cobitolimod phase III program - InDex Pharmaceuticals · Independent Data Monitoring Committee (DMC) advises that cobitolimod is unlikely to meet the primary endpoint upon completion of Induction Study 1 · More information regarding next steps will be provided once a thorough analysis of the data from Induction Study 1 has been completed 21 November, ...

We are looking forward to participate at the Redeye Life Science Day 2023 on November 23 at 11:20 CET.

Our CEO, Jenny Sundqvist, will present and be joined by leadership team colleagues to answer questions about the company and our phase III program CONCLUDE, which is evaluating cobitolimod as a novel treatment for patients with moderate to severe, left-sided ulcerative colitis.

Watch the livestream via the link below where the presentation also will be available afterwards.

The presentation will also be available afterwards on InDex Pharmaceuticals' website: www.indexpharma.com

More information below.

Redeye Life Science Day 2023 - Redeye On 23 November, we will bring together 40+ Nordic companies for Life Science Day, a live-streamed event where investors, businesses, and experts co-create the industry’s future.